Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma

Yuri Akishima-Fukasawa, Yoshinori Ino, Yukihiro Nakanishi, Ayaka Miura, Yoshihiro Moriya, Tadashi Kondo, Yae Kanai, Setsuo Hirohashi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

To assess the expression of a cancer-associated fibroblasts (CAFs) marker as an indicator of prognosis, we raised anti-protein gene product 9.5 (PGP9.5) monoclonal antibody against cultured fibroblasts. PGP9.5 expression in cultured normal fibroblasts was increased by transforming growth factor β stimulation, indicating the phenotypic alteration to activated fibroblast. We immunohistochemically evaluated PGP9.5 expression with the CAFs of 110 colorectal cancer cases under T3 stage. PGP9.5 immunoreactivity in 30% or more of CAFs was defined as high PGP9.5 expression, and the other cases were considered as having low PGP9.5 expression. Patients with high PGP9.5 expression (42.7%) had significantly shorter survival and a higher incidence of recurrence than the low PGP9.5 expression group (P = .002 and P < .001, respectively). Multivariate analysis indicated PGP9.5 expression as an independent prognostic factor for overall and recurrence-free survival partly as well as lymph node metastasis. These results indicate that PGP9.5 expression in CAFs is a helpful finding to represent the overall biologic behavior of advanced colorectal cancer.

Original languageEnglish
Pages (from-to)71-79
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume134
Issue number1
DOIs
Publication statusPublished - 2010 Jul
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Proteins
Fibroblasts
Cancer-Associated Fibroblasts
Recurrence
Survival
Transforming Growth Factors
Multivariate Analysis
Lymph Nodes
Monoclonal Antibodies
Neoplasm Metastasis
Incidence

Keywords

  • Cancer-associated fibroblast
  • Colorectal cancer
  • Immunohistochemistry
  • PGP9.5
  • Prognosis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Akishima-Fukasawa, Y., Ino, Y., Nakanishi, Y., Miura, A., Moriya, Y., Kondo, T., ... Hirohashi, S. (2010). Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma. American Journal of Clinical Pathology, 134(1), 71-79. https://doi.org/10.1309/AJCPRJP39MIDSGBH

Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma. / Akishima-Fukasawa, Yuri; Ino, Yoshinori; Nakanishi, Yukihiro; Miura, Ayaka; Moriya, Yoshihiro; Kondo, Tadashi; Kanai, Yae; Hirohashi, Setsuo.

In: American Journal of Clinical Pathology, Vol. 134, No. 1, 07.2010, p. 71-79.

Research output: Contribution to journalArticle

Akishima-Fukasawa, Y, Ino, Y, Nakanishi, Y, Miura, A, Moriya, Y, Kondo, T, Kanai, Y & Hirohashi, S 2010, 'Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma', American Journal of Clinical Pathology, vol. 134, no. 1, pp. 71-79. https://doi.org/10.1309/AJCPRJP39MIDSGBH
Akishima-Fukasawa, Yuri ; Ino, Yoshinori ; Nakanishi, Yukihiro ; Miura, Ayaka ; Moriya, Yoshihiro ; Kondo, Tadashi ; Kanai, Yae ; Hirohashi, Setsuo. / Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma. In: American Journal of Clinical Pathology. 2010 ; Vol. 134, No. 1. pp. 71-79.
@article{7ce7e80a8af1459ab9a061205b6a474e,
title = "Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma",
abstract = "To assess the expression of a cancer-associated fibroblasts (CAFs) marker as an indicator of prognosis, we raised anti-protein gene product 9.5 (PGP9.5) monoclonal antibody against cultured fibroblasts. PGP9.5 expression in cultured normal fibroblasts was increased by transforming growth factor β stimulation, indicating the phenotypic alteration to activated fibroblast. We immunohistochemically evaluated PGP9.5 expression with the CAFs of 110 colorectal cancer cases under T3 stage. PGP9.5 immunoreactivity in 30{\%} or more of CAFs was defined as high PGP9.5 expression, and the other cases were considered as having low PGP9.5 expression. Patients with high PGP9.5 expression (42.7{\%}) had significantly shorter survival and a higher incidence of recurrence than the low PGP9.5 expression group (P = .002 and P < .001, respectively). Multivariate analysis indicated PGP9.5 expression as an independent prognostic factor for overall and recurrence-free survival partly as well as lymph node metastasis. These results indicate that PGP9.5 expression in CAFs is a helpful finding to represent the overall biologic behavior of advanced colorectal cancer.",
keywords = "Cancer-associated fibroblast, Colorectal cancer, Immunohistochemistry, PGP9.5, Prognosis",
author = "Yuri Akishima-Fukasawa and Yoshinori Ino and Yukihiro Nakanishi and Ayaka Miura and Yoshihiro Moriya and Tadashi Kondo and Yae Kanai and Setsuo Hirohashi",
year = "2010",
month = "7",
doi = "10.1309/AJCPRJP39MIDSGBH",
language = "English",
volume = "134",
pages = "71--79",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

TY - JOUR

T1 - Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma

AU - Akishima-Fukasawa, Yuri

AU - Ino, Yoshinori

AU - Nakanishi, Yukihiro

AU - Miura, Ayaka

AU - Moriya, Yoshihiro

AU - Kondo, Tadashi

AU - Kanai, Yae

AU - Hirohashi, Setsuo

PY - 2010/7

Y1 - 2010/7

N2 - To assess the expression of a cancer-associated fibroblasts (CAFs) marker as an indicator of prognosis, we raised anti-protein gene product 9.5 (PGP9.5) monoclonal antibody against cultured fibroblasts. PGP9.5 expression in cultured normal fibroblasts was increased by transforming growth factor β stimulation, indicating the phenotypic alteration to activated fibroblast. We immunohistochemically evaluated PGP9.5 expression with the CAFs of 110 colorectal cancer cases under T3 stage. PGP9.5 immunoreactivity in 30% or more of CAFs was defined as high PGP9.5 expression, and the other cases were considered as having low PGP9.5 expression. Patients with high PGP9.5 expression (42.7%) had significantly shorter survival and a higher incidence of recurrence than the low PGP9.5 expression group (P = .002 and P < .001, respectively). Multivariate analysis indicated PGP9.5 expression as an independent prognostic factor for overall and recurrence-free survival partly as well as lymph node metastasis. These results indicate that PGP9.5 expression in CAFs is a helpful finding to represent the overall biologic behavior of advanced colorectal cancer.

AB - To assess the expression of a cancer-associated fibroblasts (CAFs) marker as an indicator of prognosis, we raised anti-protein gene product 9.5 (PGP9.5) monoclonal antibody against cultured fibroblasts. PGP9.5 expression in cultured normal fibroblasts was increased by transforming growth factor β stimulation, indicating the phenotypic alteration to activated fibroblast. We immunohistochemically evaluated PGP9.5 expression with the CAFs of 110 colorectal cancer cases under T3 stage. PGP9.5 immunoreactivity in 30% or more of CAFs was defined as high PGP9.5 expression, and the other cases were considered as having low PGP9.5 expression. Patients with high PGP9.5 expression (42.7%) had significantly shorter survival and a higher incidence of recurrence than the low PGP9.5 expression group (P = .002 and P < .001, respectively). Multivariate analysis indicated PGP9.5 expression as an independent prognostic factor for overall and recurrence-free survival partly as well as lymph node metastasis. These results indicate that PGP9.5 expression in CAFs is a helpful finding to represent the overall biologic behavior of advanced colorectal cancer.

KW - Cancer-associated fibroblast

KW - Colorectal cancer

KW - Immunohistochemistry

KW - PGP9.5

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=77954466410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954466410&partnerID=8YFLogxK

U2 - 10.1309/AJCPRJP39MIDSGBH

DO - 10.1309/AJCPRJP39MIDSGBH

M3 - Article

C2 - 20551269

AN - SCOPUS:77954466410

VL - 134

SP - 71

EP - 79

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 1

ER -